AKR1B10 and hepatocellular carcinoma: Over the past decade, a number of experimental and clinical studies have emerged in the literature implicating AKR1B10 in the development and progression of HCC and the development of acquired resistance to HCC chemotherapeutic agents, and supporting a role for this enzyme as a biomarker for HCC diagnosis and prognosis.